Gene Therapy for Prostate Cancer

References

• . Johnson LE, Frye TP, Chinnasamy N, Chinnasamy D, McNeel DG. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells. Cancer Immunol Immunother. 2007;56(6):885–895
   PubMed Web of Science ®Google Scholar
• . Jemal A, Tiwari RC, Murray T, ; American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin. 2004;54(1):8–29
   PubMed Web of Science ®Google Scholar
• . Lassi K, Dawson NA. Update on castrate-resistant prostate cancer: 2010. Curr Opin Oncol. 2010;22(3):263–267
   PubMed Web of Science ®Google Scholar
• . Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med. 1993;118(10):793–803
   PubMed Web of Science ®Google Scholar
• . Scher HI, Heller G. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology. 2000;55(3):323–327
   PubMed Web of Science ®Google Scholar
• . Miller AM, Pisa P. Tumor escape mechanisms in prostate cancer. Cancer Immunol Immunother. 2007;56(1):81–87
   PubMed Web of Science ®Google Scholar
• . Buhles A, Collins SA, van Pijkeren JP, . Anti-metastatic effects of viral and non-viral mediated Nk4 delivery to tumours. Genet Vaccines Ther. 2009;7:5
   PubMedGoogle Scholar
• . Shi F, Rakhmilevich AL, Heise CP, . Intratumoral injection of interleukin-12 plasmid DNA, either naked or in complex with cationic lipid, results in similar tumor regression in a murine model. Mol Cancer Ther. 2002;1(11):949–957
   PubMed Web of Science ®Google Scholar
• . Walther W, Stein U, Fichtner I, . Intratumoral low-volume jet-injection for efficient nonviral gene transfer. Mol Biotechnol. 2002;21(2):105–115
   PubMed Web of Science ®Google Scholar
• . Kawabata K, Takakura Y, Hashida M. The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharm Res. 1995;12(6):825–830
   PubMed Web of Science ®Google Scholar
• . Lechardeur D, Sohn KJ, Haardt M, . Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer. Gene Ther. 1999;6(4):482–497
   PubMed Web of Science ®Google Scholar
• . Palffy R, Gardlik R, Hodosy J, . Bacteria in gene therapy: bactofection versus alternative gene therapy. Gene Ther. 2006;13(2):101–105
   PubMed Web of Science ®Google Scholar
• . Friedmann T. The Development of Human Gene Therapy. New York, NY: Cold Spring Harbor Laboratory Press; 1999
   Google Scholar
• . Templeton N, Lasic D, eds. Gene therapy: therapeutic mechanisms and strategies. In: Gene Therapy: Therapeutic Mechanisms and Strategies. New York, NY: Marcel Dekker, Inc.; 2000
   Google Scholar
• . Collins SA, Guinn BA, Harrison PT, Scallan MF, O'Sullivan GC, Tangney M. Viral vectors in cancer immunotherapy: which vector for which strategy? Curr Gene Ther. 2008;8(2):66–78
   PubMed Web of Science ®Google Scholar
• . Schenk E, Essand M, Bangma C. Clinical adenoviral gene therapy for prostate cancer [published online ahead of print December 10, 2009]. Hum Gene Ther.
   Google Scholar
• . de Vrij J, Willemsen RA, Lindholm L, Hoeben RC. Adenovirus-derived vectors for prostate cancer gene therapy [published online ahead of print March 25, 2010]. Hum Gene Ther.
   Google Scholar
• . Cusack JC Jr, Tanabe KK. Introduction to cancer gene therapy. Surg Oncol Clin N Am. 2002;11(3):497–519, v
   PubMedGoogle Scholar
• . Lundstrom K. Latest development in viral vectors for gene therapy. Trends Biotechnol. 2003;21(3):117–122
   PubMed Web of Science ®Google Scholar
• . Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003;4(5):346–358
   PubMed Web of Science ®Google Scholar
• . Emtage PC, Wan Y, Hitt M, . Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum Gene Ther. 1999;10(5):697–709
   PubMed Web of Science ®Google Scholar
• . Nasu Y, Bangma CH, Hull GW, . Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Ther. 1999;6(3):338–349
   PubMed Web of Science ®Google Scholar
• . Yamamoto M, Curiel DT. Cancer gene therapy. Technol Cancer Res Treat. 2005;4(4):315–330
   PubMed Web of Science ®Google Scholar
• . Morrow JF, Cohen SN, Chang AC, Boyer HW, Goodman HM, Helling RB. Replication and transcription of eukaryotic DNA in Escherichia coli. Proc Natl Acad Sci U S A. 1974;71(5):1743–1747
   PubMed Web of Science ®Google Scholar
• . Walsh M, Tangney M, O'Neill MJ, . Evaluation of cellular uptake and gene transfer efficiency of pegylated poly-L-lysine compacted DNA: implications for cancer gene therapy. Mol Pharm. 2006;3(6):644–653
   PubMedGoogle Scholar
• . Ahmad S, Casey G, Sweeney P, Tangney M, O'Sullivan GC. Optimised electroporation mediated DNA vaccination for treatment of prostate cancer. Genet Vaccines Ther. 2010;8(1):1
   PubMedGoogle Scholar
• . Tangney M, Casey G, Larkin JO, . Non-viral in vivo immune gene therapy of cancer: combined strategies for treatment of systemic disease. Cancer Immunol Immunother. 2006;55(11):1443–1450
   PubMed Web of Science ®Google Scholar
• . Casey G, Cashman JP, Morrissey D, . Sonoporation mediated immunogene therapy of solid tumours. Ultrasound Med Biol. 2010;36(3):430–440
   PubMed Web of Science ®Google Scholar
• . Tangney M, Gahan CG. Listeria monocytogenes as a vector for anti-cancer therapies. Curr Gene Ther. 2010;10(1):46–55
   PubMed Web of Science ®Google Scholar
• . Vassaux G, Nitcheu J, Jezzard S, Lemoine NR. Bacterial gene therapy strategies. J Pathol. 2006;208(2):290–298
   PubMed Web of Science ®Google Scholar
• . Moreno M, Kramer MG, Yim L, Chabalgoity JA. Salmonella as live trojan horse for vaccine development and cancer gene therapy. Curr Gene Ther. 2010;10(1):56–76
   PubMed Web of Science ®Google Scholar
• . Buttaro C, Fruehauf JH. Engineered E. coli as vehicles for targeted therapeutics. Curr Gene Ther. 2010;10(1):27–33
   PubMed Web of Science ®Google Scholar
• . Tangney M, Gahan CG. Listeria monocytogenes as a vector for anti-cancer therapies. Curr Gene Ther. 2010;10(1):46–55
   PubMed Web of Science ®Google Scholar
• . Alton EW, Middleton PG, Caplen NJ, . Non-invasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice. Nat Genet. 1993;5(2):135–142
   PubMed Web of Science ®Google Scholar
• . Huber PE, Pfisterer P. In vitro and in vivo transfection of plasmid DNA in the Dunning prostate tumor R3327-AT1 is enhanced by focused ultrasound. Gene Ther. 2000;7(17):1516–1525
   PubMed Web of Science ®Google Scholar
• . Taniyama Y, Tachibana K, Hiraoka K, . Development of safe and efficient novel nonviral gene transfer using ultrasound: enhancement of transfection efficiency of naked plasmid DNA in skeletal muscle. Gene Ther. 2002;9(6):372–380
   PubMed Web of Science ®Google Scholar
• . Duvshani-Eshet M, Benny O, Morgenstern A, Machluf M. Therapeutic ultrasound facilitates antiangiogenic gene delivery and inhibits prostate tumor growth. Mol Cancer Ther. 2007;6(8):2371–2382
   PubMed Web of Science ®Google Scholar
• . Clapé C, Fritz V, Henriquet C, . miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS One. 2009;4(10):e7542
   PubMed Web of Science ®Google Scholar
• . Mikata K, Uemura H, Ohuchi H, Ohta S, Nagashima Y, Kubota Y. Inhibition of growth of human prostate cancer xenograft by transfection of p53 gene: gene transfer by electroporation. Mol Cancer Ther. 2002;1(4):247–252
   PubMed Web of Science ®Google Scholar
• . Wu F, Wang ZB, Chen WZ, . Extracorporeal high intensity focused ultrasound ablation in the treatment of patients with large hepatocellular carcinoma. Ann Surg Oncol. 2004;11(12):1061–1069
   PubMed Web of Science ®Google Scholar
• . Morrissey D, O'Sullivan GC, Tangney M. Tumour targeting with systemically administered bacteria. Curr Gene Ther. 2010;10(1):3–14
   PubMed Web of Science ®Google Scholar
• . Cronin M, Morrissey D, Rajendran S, . Orally administered bifidobacteria as a vehicle for delivery of agents to systemic tumours [published online ahead of print April 13, 2010]. Mol Ther.
   Google Scholar
• . Mengesha A, Wei JZ, Zhou SF, Wei MQ. Clostridial spores to treat solid tumours—potential for a new therapeutic modality. Curr Gene Ther. 2010;10(1)15–26
   PubMed Web of Science ®Google Scholar
• . Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci U S A. 2001;98(26):15155–15160
   PubMed Web of Science ®Google Scholar
• . van Pijkeren JP, Morrissey D, Monk IR, . A novel listeria monocytogenes-based DNA delivery system for cancer gene therapy. Hum Gene Ther. 2010;21(4):405–416
   PubMed Web of Science ®Google Scholar
• . Zhao M, Yang M, Li XM, . Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci U S A. 2005;102(3):755–760
   PubMed Web of Science ®Google Scholar
• . Kasahara N, Dozy AM, Kan YW. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science. 1994;266(5189):1373–1376
   PubMed Web of Science ®Google Scholar
• . Han X, Kasahara N, Kan YW. Ligand-directed retroviral targeting of human breast cancer cells. Proc Natl Acad Sci U S A. 1995;92(21):9747–9751
   PubMed Web of Science ®Google Scholar
• . Cosset FL, Morling FJ, Takeuchi Y, Weiss RA, Collins MK, Russell SJ. Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol. 1995;69(10):6314–6322
   PubMed Web of Science ®Google Scholar
• . Marin M, Noël D, Valsesia-Wittman S, . Targeted infection of human cells via major histocompatibility complex class I molecules by Moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins. J Virol. 1996;70(5):2957–2962
   PubMed Web of Science ®Google Scholar
• . Kircheis R, Schuller S, Brunner S, . Polycation-based DNA complexes for tumor-targeted gene delivery in vivo. J Gene Med. 1999;1(2):111–120
   PubMed Web of Science ®Google Scholar
• . Tam P, Monck M, Lee D, . Stabilized plasmid-lipid particles for systemic gene therapy. Gene Ther. 2000;7(21):1867–1874
   PubMed Web of Science ®Google Scholar
• . Monck MA, Mori A, Lee D, . Stabilized plasmid-lipid particles: pharmacokinetics and plasmid delivery to distal tumors following intravenous injection. J Drug Target. 2000;7(6):439–452
   PubMed Web of Science ®Google Scholar
• . Xu L, Pirollo KF, Tang WH, Rait A, Chang EH. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum Gene Ther. 1999;10(18):2941–2952
   PubMed Web of Science ®Google Scholar
• . Lu Y. Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer. Adv Drug Deliv Rev. 2009;61(7–8):572–588
   PubMed Web of Science ®Google Scholar
• . Lee CH, Liu M, Sie KL, Lee MS. Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-alpha and topoisomerase II alpha in prostate cancer. Anticancer Res. 1996;16(4A):1805–1811
   PubMed Web of Science ®Google Scholar
• . Martiniello-Wilks R, Garcia-Aragon J, Daja MM, . In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Hum Gene Ther. 1998;9(11):1617–1626
   PubMed Web of Science ®Google Scholar
• . Figueiredo ML, Kao C, Wu L. Advances in preclinical investigation of prostate cancer gene therapy. Mol Ther. 2007;15(6):1053–1064
   PubMed Web of Science ®Google Scholar
• . Greenberg NM, DeMayo F, Finegold MJ, . Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A. 1995;92(8):3439–3443
   PubMed Web of Science ®Google Scholar
• . Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res. 1997;57(16):3325–3330
   PubMed Web of Science ®Google Scholar
• . Haga K, Tomioka A, Liao CP, . PTEN knockout prostate cancer as a model for experimental immunotherapy. J Urol. 2009;181(1): 354–362
   PubMed Web of Science ®Google Scholar
• . Shirakawa T, Fujisawa M, Gotoh A. Gene therapy in prostate cancer: past, present and future. Front Biosci. 2008;13:2115–2119
   PubMed Web of Science ®Google Scholar
• . MacRae EJ, Giannoudis A, Ryan R, . Gene therapy for prostate cancer: current strategies and new cell-based approaches. Prostate. 2006;66(5):470–494
   PubMed Web of Science ®Google Scholar
• . Eder IE, Haag P, Bartsch G, Klocker H. Gene therapy strategies in prostate cancer. Curr Gene Ther. 2005;5(1):1–10
   PubMed Web of Science ®Google Scholar
• . Freytag SO, Stricker H, Movsas B, Kim JH. Prostate cancer gene therapy clinical trials. Mol Ther. 2007;15(6):1042–1052
   PubMed Web of Science ®Google Scholar
• . Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407(6805):770–776
   PubMed Web of Science ®Google Scholar
• . Lowe SL, Rubinchik S, Honda T, McDonnell TJ, Dong JY, Norris JS. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells. Gene Ther. 2001;8(18):1363–1371
   PubMed Web of Science ®Google Scholar
• . Zhang Y, Yu J, Unni E, . Monogene and polygene therapy for the treatment of experimental prostate cancers by use of apoptotic genes bax and bad driven by the prostate-specific promoter ARR(2)PB. Hum Gene Ther. 2002;13(17):2051–2064
   PubMed Web of Science ®Google Scholar
• . Cowen D, Salem N, Ashoori F, . Prostate cancer radiosensitization in vivo with adenovirus-mediated p53 gene therapy. Clin Cancer Res. 2000;6(11):4402–4408
   PubMed Web of Science ®Google Scholar
• . Pisters LL, Pettaway CA, Troncoso P, . Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res. 2004;10(8):2587–2593
   PubMed Web of Science ®Google Scholar
• . Zheng JY, Chen D, Chan J, Yu D, Ko E, Pang S. Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A. Cancer Gene Ther. 2003;10(10):764–770
   PubMed Web of Science ®Google Scholar
• . Freeman SM. Suicide gene therapy. Adv Exp Med Biol. 2000;465:411–422
   PubMed Web of Science ®Google Scholar
• . Vile RG, Nelson JA, Castleden S, Chong H, Hart IR. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 1994;54(23):6228–6234
   PubMed Web of Science ®Google Scholar
• . Yoshimura I, Suzuki S, Tadakuma T, Hayakawa M. Suicide gene therapy on LNCaP human prostate cancer cells. Int J Urol. 2001;8(7):S5–S8
   Web of Science ®Google Scholar
• . Chen L, Pulsipher M, Chen D, . Selective transgene expression for detection and elimination of contaminating carcinoma cells in hematopoietic stem cell sources. J Clin Invest. 1996;98(11):2539–2548
   PubMed Web of Science ®Google Scholar
• . Eaton JD, Perry MJ, Todryk SM, . Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques. Gene Ther. 2001;8(7):557–567
   PubMed Web of Science ®Google Scholar
• . Ikegami S, Tadakuma T, Ono T, . Treatment efficiency of a suicide gene therapy using prostate-specific membrane antigen promoter/enhancer in a castrated mouse model of prostate cancer. Cancer Sci. 2004;95(4):367–370
   PubMed Web of Science ®Google Scholar
• . Ikegami S, Tadakuma T, Suzuki S, Yoshimura I, Asano T, Hayakawa M. Development of gene therapy using prostate-specific membrane antigen promoter/enhancer with Cre Recombinase/LoxP system for prostate cancer cells under androgen ablation condition. Jpn J Cancer Res. 2002;93(10):1154–1163
   PubMedGoogle Scholar
• . Zhang Z, Yin L, Zhang Y, Zhao F. In situ transduction of cytosine deaminase gene followed by systemic use of 5-fluorocytosine inhibits tumor growth and metastasis in orthotopic prostate cancer mouse models. Chin Med J (Engl). 2002;115(2):227–231
   PubMed Web of Science ®Google Scholar
• . Martiniello-Wilks R, Wang XY, Voeks DJ, . Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer. J Gene Med. 2004;6(12):1343–1357
   PubMed Web of Science ®Google Scholar
• . Nasu Y, Saika T, Ebara S, . Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy. Mol Ther. 2007;15(4):834–840
   PubMed Web of Science ®Google Scholar
• . Both GW. Recent progress in gene-directed enzyme prodrug therapy: an emerging cancer treatment. Curr Opin Mol Ther. 2009;11(4):421–432
   PubMedGoogle Scholar
• . Alain T, Hirasawa K, Pon KJ, . Reovirus therapy of lymphoid malignancies. Blood. 2002;100(12):4146–4153
   PubMed Web of Science ®Google Scholar
• . Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossakowska A, Lee PW. Oncolytic reovirus against ovarian and colon cancer. Cancer Res. 2002;62(6):1696–1701
   PubMed Web of Science ®Google Scholar
• . Norman KL, Coffey MC, Hirasawa K, . Reovirus oncolysis of human breast cancer. Hum Gene Ther. 2002;13(5):641–652
   PubMed Web of Science ®Google Scholar
• . Mullen JT, Tanabe KK. Viral oncolysis. Oncologist. 2002;7(2):106–119
   PubMed Web of Science ®Google Scholar
• . Phuangsab A, Lorence RM, Reichard KW, Peeples ME, Walter RJ. Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett. 2001;172(1):27–36
   PubMed Web of Science ®Google Scholar
• . Stojdl DF, Lichty B, Knowles S, . Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 2000;6(7):821–825
   PubMed Web of Science ®Google Scholar
• . Stojdl DF, Lichty BD, tenOever BR, . VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell. 2003;4(4):263–275
   PubMed Web of Science ®Google Scholar
• . Haag A, Menten P, Van Damme J, Dinsart C, Rommelaere J, Cornelis JJ. Highly efficient transduction and expression of cytokine genes in human tumor cells by means of autonomous parvovirus vectors; generation of antitumor responses in recipient mice. Hum Gene Ther. 2000;11(4):597–609
   PubMed Web of Science ®Google Scholar
• . Herrero YC, Cornelis JJ, Herold-Mende C, Rommelaere J, Schlehofer JR, Geletneky K. Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing. Int J Cancer. 2004;109(1):76–84
   PubMed Web of Science ®Google Scholar
• . Moehler M, Blechacz B, Weiskopf N, . Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectors. Cancer Gene Ther. 2001;8(3):158–167
   PubMed Web of Science ®Google Scholar
• . Comins C, Heinemann L, Harrington K, Melcher A, De Bono J, Pandha H. Reovirus: viral therapy for cancer ‘as nature intended’. Clin Oncol (R Coll Radiol). 2008;20(7):548–554
   PubMed Web of Science ®Google Scholar
• . Norman KL, Lee PW. Not all viruses are bad guys: the case for reovirus in cancer therapy. Drug Discov Today. 2005;10(12):847–855
   PubMed Web of Science ®Google Scholar
• . Thirukkumaran CM, Nodwell MJ, Hirasawa K, . Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic. Cancer Res. 2010;70(6):2435–2444
   PubMed Web of Science ®Google Scholar
• . Heise C, Hermiston T, Johnson L, . An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med. 2000;6(10):1134–1139
   PubMed Web of Science ®Google Scholar
• . DeWeese TL, van der Poel H, Li S, . A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 2001;61(20):7464–7472
   PubMed Web of Science ®Google Scholar
• . Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 1997;57(13):2559–2563
   PubMed Web of Science ®Google Scholar
• . Yu DC, Chen Y, Seng M, Dilley J, Henderson DR. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. 1999;59(17):4200–4203
   PubMed Web of Science ®Google Scholar
• . Small EJ, Carducci MA, Burke JM, . A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther. 2006;14(1):107–117
   PubMed Web of Science ®Google Scholar
• . Thirukkumaran CM, Nodwell MJ, Hirasawa K, . Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic. Cancer Res. 2010;70(6):2435–2444
   PubMed Web of Science ®Google Scholar
• . Liu C, Zhang Y, Liu MM, . Evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer. Int J Radiat Biol. 2010;86(3):220–229
   PubMed Web of Science ®Google Scholar
• . Cozzi PJ, Burke PB, Bhargav A, . Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses. Prostate. 2002;53(2):95–100
   PubMed Web of Science ®Google Scholar
• . Oyama M, Ohigashi T, Hoshi M, Murai M, Uyemura K, Yazaki T. Oncolytic viral therapy for human prostate cancer by conditionally replicating herpes simplex virus 1 vector G207. Jpn J Cancer Res. 2000;91(12):1339–1344
   PubMedGoogle Scholar
• . Murphy J, O'Sullivan GC, Lee G, . The inflammatory response within Dukes' B colorectal cancers: implications for progression of micrometastases and patient survival. Am J Gastroenterol. 2000;95(12):3607–3614
   PubMed Web of Science ®Google Scholar
• . Borrello I, Pardoll D. GM-CSF-based cellular vaccines: a review of the clinical experience. Cytokine Growth Factor Rev. 2002;13(2):185–193
   PubMed Web of Science ®Google Scholar
• . O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med. 1996;184(3):1075–1082
   PubMed Web of Science ®Google Scholar
• . Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol. 2002;2(6):389–400
   PubMed Web of Science ®Google Scholar
• . Bui JD, Schreiber RD. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol. 2007;19(2):203–208
   PubMed Web of Science ®Google Scholar
• . Weiner LM. Cancer immunotherapy—the endgame begins. N Engl J Med. 2008;358(25):2664–2665
   PubMed Web of Science ®Google Scholar
• . Simons JW, Mikhak B, Chang JF, . Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 1999;59(20):5160–5168
   PubMed Web of Science ®Google Scholar
• . Eder JP, Kantoff PW, Roper K, . A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res. 2000;6(5):1632–1638
   PubMed Web of Science ®Google Scholar
• . Small EJ, Fratesi P, Reese DM, . Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000;18(23):3894–3903
   PubMed Web of Science ®Google Scholar
• . Pavlenko M, Roos AK, Lundqvist A, . A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer. 2004;91(4):688–694
   PubMed Web of Science ®Google Scholar
• . Mincheff M, Tchakarov S, Zoubak S, . Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. Eur Urol. 2000;38(2):208–217
   PubMed Web of Science ®Google Scholar
• . Yousefieh N, Hahto SM, Stephens AL, Ciavarra RP. Regulated expression of CCL21 in the prostate tumor microenvironment inhibits tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Microenviron. 2009;2(1):59–67
   PubMedGoogle Scholar
• . Trudel S, Trachtenberg J, Toi A, . A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Ther. 2003;10(10):755–763
   PubMed Web of Science ®Google Scholar
• . Belldegrun A, Tso CL, Zisman A, . Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther. 2001;12(8):883–892
   PubMed Web of Science ®Google Scholar
• . Ward JE, McNeel DG. GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther. 2007;7(12):1893–1902
   PubMed Web of Science ®Google Scholar
• . Antonarakis ES, Drake CG. Current status of immunological therapies for prostate cancer. Curr Opin Urol. 2010;20(3):241–246
   PubMed Web of Science ®Google Scholar
• . Doehn C, Böhmer T, Jocham D. Technology evaluation: Onyvax-P, Onyvax. Curr Opin Mol Ther. 2005;7(5):511–519
   PubMedGoogle Scholar
• . Copier J, Dalgleish A. Overview of tumor cell-based vaccines. Int Rev Immunol. 2006;25(5–6):297–319
   PubMed Web of Science ®Google Scholar
• . Ahmad S, Casey G, Sweeney P, Tangney M, O'Sullivan GC. Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth. Mol Ther. 2009;17(6):1101–1108
   PubMed Web of Science ®Google Scholar
• . Low L, Mander A, McCann K, . DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther. 2009;20(11):1269–1278
   PubMed Web of Science ®Google Scholar
• . MacGregor RR, Boyer JD, Ugen KE, . First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis. 1998;178(1):92–100
   PubMed Web of Science ®Google Scholar
• . Marshall DJ, San Mateo LR, Rudnick KA, . Induction of Th1-type immunity and tumor protection with a prostate-specific antigen DNA vaccine. Cancer Immunol Immunother. 2005;54(11):1082–1094
   PubMed Web of Science ®Google Scholar
• . Stevenson FK, Ottensmeier CH, Rice J. DNA vaccines against cancer come of age. Curr Opin Immunol. 2010;22(2):264–270
   PubMed Web of Science ®Google Scholar
• . Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer. 2008;8(2):108–120
   PubMed Web of Science ®Google Scholar
• . Malecki M, Kolsut P, Proczka R. Angiogenic and antiangiogenic gene therapy. Gene Ther. 2005;12( suppl 1):S159–S169
   Web of Science ®Google Scholar
• . Holleb AI, Folkman J. Tumor angiogenesis. CA Cancer J Clin. 1972;22(4):226–229
   PubMedGoogle Scholar
• . Folkman J. The vascularization of tumors. Sci Am. 1976;234(5):58–64, 70–73
   PubMed Web of Science ®Google Scholar
• . Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669–676
   PubMed Web of Science ®Google Scholar
• . McCormick F. Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer. 2001;1(2):130–141
   PubMed Web of Science ®Google Scholar
• . Feldman AL, Libutti SK. Progress in antiangiogenic gene therapy of cancer. Cancer. 2000;89(6):1181–1194
   PubMed Web of Science ®Google Scholar
• . Kim WJ, Chang CW, Lee M, Kim SW. Efficient siRNA delivery using water soluble lipopolymer for anti-angiogenic gene therapy. J Control Release. 2007;118(3):357–363
   PubMed Web of Science ®Google Scholar
• . Zhao P, Luo R, Wu J, . E10A, an adenovirus carrying human endostatin gene, in combination with docetaxel treatment inhibits prostate cancer growth and metastases [published online ahead of print October 13, 2008]. J Cell Mol Med.
   Google Scholar
• . Jin RJ, Kwak C, Lee SG, . The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts. Cancer Gene Ther. 2000;7(12):1537–1542
   PubMed Web of Science ®Google Scholar
• . Song W, Dong Z, Jin T, Mantellini MG, Núnez G, Nör JE. Cancer gene therapy with iCaspase-9 transcriptionally targeted to tumor endothelial cells. Cancer Gene Ther. 2008;15(10):667–675
   PubMed Web of Science ®Google Scholar
• . Isayeva T, Moore LD, Chanda D, Chen D, Ponnazhagan S. Tumoristatic effects of endostatin in prostate cancer is dependent on androgen receptor status. Prostate. 2009;69(10):1055–1066
   PubMed Web of Science ®Google Scholar
• . Wen Y, Giri D, Yan DH, . Prostate-specific antitumor activity by probasin promoter-directed p202 expression. Mol Carcinog. 2003;37(3):130–137
   PubMed Web of Science ®Google Scholar
• . Freytag SO, Paielli D, Wing M, . Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model. Int J Radiat Oncol Biol Phys. 2002;54(3):873–885
   PubMed Web of Science ®Google Scholar
• . Saika T, Satoh T, Kusaka N, . Route of administration influences the antitumor effects of bone marrow-derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model. Cancer Gene Ther. 2004;11(5):317–324
   PubMed Web of Science ®Google Scholar
• . Ahmad S, Casey G, Sweeney P, Tangney M, O'Sullivan GC. Optimised electroporation mediated DNA vaccination for treatment of prostate cancer. Genet Vaccines Ther. 8(1):1
   PubMedGoogle Scholar
• . Medin JA, Liang SB, Hou JW, Kelley LS, Peace DJ, Fowler DH. Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo. Cancer Gene Ther. 2005;12(6):540–551
   PubMed Web of Science ®Google Scholar
• . Herman JR, Adler HL, Aguilar-Cordova E, . In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther. 1999;10(7):1239–1249
   PubMed Web of Science ®Google Scholar
• . Miles BJ, Shalev M, Aguilar-Cordova E, . Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther. 2001;12(16):1955–1967
   PubMed Web of Science ®Google Scholar
• . Kubo H, Gardner TA, Wada Y, . Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther. 2003;14(3):227–241
   PubMed Web of Science ®Google Scholar
• . Teh BS, Ayala G, Aguilar L, . Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys. 2004;58(5):1520–1529
   PubMed Web of Science ®Google Scholar
• . Freytag SO, Stricker H, Peabody J, . Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther. 2007;15(3):636–642
   PubMed Web of Science ®Google Scholar
• . Freytag SO, Khil M, Stricker H, . Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 2002;62(17):4968–4976
   PubMed Web of Science ®Google Scholar
• . Sanda MG, Ayyagari SR, Jaffee EM, . Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol. 1994;151(3):622–628
   PubMed Web of Science ®Google Scholar
• . Sanda MG, Smith DC, Charles LG, . Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology. 1999;53(2):260–266
   PubMed Web of Science ®Google Scholar
• . Kaufman HL, Wang W, Manola J, . Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2004;22(11):2122–2132
   PubMed Web of Science ®Google Scholar
• . Pantuck AJ, van Ophoven A, Gitlitz BJ, . Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J Immunother. 2004;27(3):240–253
   PubMed Web of Science ®Google Scholar
• . Cell Genesys reports long-term survival data in Phase II trial of GVAX. Expert Rev Anticancer Ther. 2002;2(3):245–246
   Google Scholar
• . Burch PA, Croghan GA, Gastineau DA, . Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate. 2004;60(3):197–204
   PubMed Web of Science ®Google Scholar